 | • レポートコード：MRC2-11QY09052 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、146ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は腎細胞癌治療薬のグローバル市場について調査・分析したレポートです。種類別（Sutent（スニチニブ）、Nexavar（ソラフェニブ）、Votrient（パゾパニブ）、Avastin（ベバシズマブ）、Afinitor（エベロリムス）、Inlyta（アキシチニブ）、Torisel（テムシロリムス）、Proleukin（アルデスロイキン））市場規模、用途別（粘液性尿細管・紡錘細胞癌（MTSCC）、多房性嚢胞性明細胞腎細胞癌、尿細管嚢胞性腎細胞癌、甲状腺様濾胞性腎細胞癌、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別腎細胞癌治療薬の競争状況、市場シェア ・世界の腎細胞癌治療薬市場：種類別市場規模 2015年-2020年（Sutent（スニチニブ）、Nexavar（ソラフェニブ）、Votrient（パゾパニブ）、Avastin（ベバシズマブ）、Afinitor（エベロリムス）、Inlyta（アキシチニブ）、Torisel（テムシロリムス）、Proleukin（アルデスロイキン）） ・世界の腎細胞癌治療薬市場：種類別市場規模予測 2021年-2026年（Sutent（スニチニブ）、Nexavar（ソラフェニブ）、Votrient（パゾパニブ）、Avastin（ベバシズマブ）、Afinitor（エベロリムス）、Inlyta（アキシチニブ）、Torisel（テムシロリムス）、Proleukin（アルデスロイキン）） ・世界の腎細胞癌治療薬市場：用途別市場規模 2015年-2020年（粘液性尿細管・紡錘細胞癌（MTSCC）、多房性嚢胞性明細胞腎細胞癌、尿細管嚢胞性腎細胞癌、甲状腺様濾胞性腎細胞癌、その他） ・世界の腎細胞癌治療薬市場：用途別市場規模予測 2021年-2026年（粘液性尿細管・紡錘細胞癌（MTSCC）、多房性嚢胞性明細胞腎細胞癌、尿細管嚢胞性腎細胞癌、甲状腺様濾胞性腎細胞癌、その他） ・北米の腎細胞癌治療薬市場分析：米国、カナダ ・ヨーロッパの腎細胞癌治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの腎細胞癌治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の腎細胞癌治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの腎細胞癌治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Merck & Co., Inc.、Exelixis Inc、Argus Therapeutics, Inc.、Bristol-Myers Squibb、Genentech、Immatics Biotechnologies、AVEO Oncology、Eisai、Acceleron、Rexahn Pharmaceuticals、Bionomics、Cerulean Pharma Inc、Celldex Therapeutics、TVAX Biomedical、TRACON Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Renal Cell Cacinoma Drugs Market
The global Renal Cell Cacinoma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Renal Cell Cacinoma Drugs Scope and Market Size
Renal Cell Cacinoma Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Renal Cell Cacinoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Renal Cell Cacinoma Drugs market is segmented into
Sutent(Sunitinib)
Nexavar(Sorafenib)
Votrient(Pazopanib)
Avastin(Bevacizumab)
Afinitor(Everolimus)
Inlyta(Axitinib)
Torisel(Temsirolimus)
Proleukin(Aldesleukin)
Segment by Application, the Renal Cell Cacinoma Drugs market is segmented into
Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
Multilocular Cystic Clear Cell Renal Cell Carcinoma
Tubulocystic Renal Cell Carcinoma
Thyroid-Like Follicular Renal Cell Carcinoma
Others
Regional and Country-level Analysis
The Renal Cell Cacinoma Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Renal Cell Cacinoma Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Renal Cell Cacinoma Drugs Market Share Analysis
Renal Cell Cacinoma Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Renal Cell Cacinoma Drugs business, the date to enter into the Renal Cell Cacinoma Drugs market, Renal Cell Cacinoma Drugs product introduction, recent developments, etc.
The major vendors covered:
Merck & Co., Inc.
Exelixis Inc
Argus Therapeutics, Inc.
Bristol-Myers Squibb
Genentech
Immatics Biotechnologies
AVEO Oncology
Eisai
Acceleron
Rexahn Pharmaceuticals
Bionomics
Cerulean Pharma Inc
Celldex Therapeutics
TVAX Biomedical
TRACON Pharmaceuticals
1 Study Coverage
1.1 Renal Cell Cacinoma Drugs Product Introduction
1.2 Market Segments
1.3 Key Renal Cell Cacinoma Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Renal Cell Cacinoma Drugs Market Size Growth Rate by Type
1.4.2 Sutent(Sunitinib)
1.4.3 Nexavar(Sorafenib)
1.4.4 Votrient(Pazopanib)
1.4.5 Avastin(Bevacizumab)
1.4.6 Afinitor(Everolimus)
1.4.7 Inlyta(Axitinib)
1.4.8 Torisel(Temsirolimus)
1.4.9 Proleukin(Aldesleukin)
1.5 Market by Application
1.5.1 Global Renal Cell Cacinoma Drugs Market Size Growth Rate by Application
1.5.2 Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
1.5.3 Multilocular Cystic Clear Cell Renal Cell Carcinoma
1.5.4 Tubulocystic Renal Cell Carcinoma
1.5.5 Thyroid-Like Follicular Renal Cell Carcinoma
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Renal Cell Cacinoma Drugs Market Size, Estimates and Forecasts
2.1.1 Global Renal Cell Cacinoma Drugs Revenue 2015-2026
2.1.2 Global Renal Cell Cacinoma Drugs Sales 2015-2026
2.2 Global Renal Cell Cacinoma Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Renal Cell Cacinoma Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Renal Cell Cacinoma Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Renal Cell Cacinoma Drugs Competitor Landscape by Players
3.1 Renal Cell Cacinoma Drugs Sales by Manufacturers
3.1.1 Renal Cell Cacinoma Drugs Sales by Manufacturers (2015-2020)
3.1.2 Renal Cell Cacinoma Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Renal Cell Cacinoma Drugs Revenue by Manufacturers
3.2.1 Renal Cell Cacinoma Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Renal Cell Cacinoma Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Renal Cell Cacinoma Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Renal Cell Cacinoma Drugs Revenue in 2019
3.2.5 Global Renal Cell Cacinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Renal Cell Cacinoma Drugs Price by Manufacturers
3.4 Renal Cell Cacinoma Drugs Manufacturing Base Distribution, Product Types
3.4.1 Renal Cell Cacinoma Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Renal Cell Cacinoma Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Renal Cell Cacinoma Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Renal Cell Cacinoma Drugs Market Size by Type (2015-2020)
4.1.1 Global Renal Cell Cacinoma Drugs Sales by Type (2015-2020)
4.1.2 Global Renal Cell Cacinoma Drugs Revenue by Type (2015-2020)
4.1.3 Renal Cell Cacinoma Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Renal Cell Cacinoma Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Renal Cell Cacinoma Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Renal Cell Cacinoma Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Renal Cell Cacinoma Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Renal Cell Cacinoma Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Renal Cell Cacinoma Drugs Market Size by Application (2015-2020)
5.1.1 Global Renal Cell Cacinoma Drugs Sales by Application (2015-2020)
5.1.2 Global Renal Cell Cacinoma Drugs Revenue by Application (2015-2020)
5.1.3 Renal Cell Cacinoma Drugs Price by Application (2015-2020)
5.2 Renal Cell Cacinoma Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Renal Cell Cacinoma Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Renal Cell Cacinoma Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Renal Cell Cacinoma Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Renal Cell Cacinoma Drugs by Country
6.1.1 North America Renal Cell Cacinoma Drugs Sales by Country
6.1.2 North America Renal Cell Cacinoma Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Renal Cell Cacinoma Drugs Market Facts & Figures by Type
6.3 North America Renal Cell Cacinoma Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Renal Cell Cacinoma Drugs by Country
7.1.1 Europe Renal Cell Cacinoma Drugs Sales by Country
7.1.2 Europe Renal Cell Cacinoma Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Renal Cell Cacinoma Drugs Market Facts & Figures by Type
7.3 Europe Renal Cell Cacinoma Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Renal Cell Cacinoma Drugs by Region
8.1.1 Asia Pacific Renal Cell Cacinoma Drugs Sales by Region
8.1.2 Asia Pacific Renal Cell Cacinoma Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Renal Cell Cacinoma Drugs Market Facts & Figures by Type
8.3 Asia Pacific Renal Cell Cacinoma Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Renal Cell Cacinoma Drugs by Country
9.1.1 Latin America Renal Cell Cacinoma Drugs Sales by Country
9.1.2 Latin America Renal Cell Cacinoma Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Renal Cell Cacinoma Drugs Market Facts & Figures by Type
9.3 Central & South America Renal Cell Cacinoma Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Renal Cell Cacinoma Drugs by Country
10.1.1 Middle East and Africa Renal Cell Cacinoma Drugs Sales by Country
10.1.2 Middle East and Africa Renal Cell Cacinoma Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Renal Cell Cacinoma Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Renal Cell Cacinoma Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Merck & Co., Inc.
11.1.1 Merck & Co., Inc. Corporation Information
11.1.2 Merck & Co., Inc. Description and Business Overview
11.1.3 Merck & Co., Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Merck & Co., Inc. Renal Cell Cacinoma Drugs Products Offered
11.1.5 Merck & Co., Inc. Related Developments
11.2 Exelixis Inc
11.2.1 Exelixis Inc Corporation Information
11.2.2 Exelixis Inc Description and Business Overview
11.2.3 Exelixis Inc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Exelixis Inc Renal Cell Cacinoma Drugs Products Offered
11.2.5 Exelixis Inc Related Developments
11.3 Argus Therapeutics, Inc.
11.3.1 Argus Therapeutics, Inc. Corporation Information
11.3.2 Argus Therapeutics, Inc. Description and Business Overview
11.3.3 Argus Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Products Offered
11.3.5 Argus Therapeutics, Inc. Related Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Corporation Information
11.4.2 Bristol-Myers Squibb Description and Business Overview
11.4.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bristol-Myers Squibb Renal Cell Cacinoma Drugs Products Offered
11.4.5 Bristol-Myers Squibb Related Developments
11.5 Genentech
11.5.1 Genentech Corporation Information
11.5.2 Genentech Description and Business Overview
11.5.3 Genentech Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Genentech Renal Cell Cacinoma Drugs Products Offered
11.5.5 Genentech Related Developments
11.6 Immatics Biotechnologies
11.6.1 Immatics Biotechnologies Corporation Information
11.6.2 Immatics Biotechnologies Description and Business Overview
11.6.3 Immatics Biotechnologies Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Immatics Biotechnologies Renal Cell Cacinoma Drugs Products Offered
11.6.5 Immatics Biotechnologies Related Developments
11.7 AVEO Oncology
11.7.1 AVEO Oncology Corporation Information
11.7.2 AVEO Oncology Description and Business Overview
11.7.3 AVEO Oncology Sales, Revenue and Gross Margin (2015-2020)
11.7.4 AVEO Oncology Renal Cell Cacinoma Drugs Products Offered
11.7.5 AVEO Oncology Related Developments
11.8 Eisai
11.8.1 Eisai Corporation Information
11.8.2 Eisai Description and Business Overview
11.8.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Eisai Renal Cell Cacinoma Drugs Products Offered
11.8.5 Eisai Related Developments
11.9 Acceleron
11.9.1 Acceleron Corporation Information
11.9.2 Acceleron Description and Business Overview
11.9.3 Acceleron Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Acceleron Renal Cell Cacinoma Drugs Products Offered
11.9.5 Acceleron Related Developments
11.10 Rexahn Pharmaceuticals
11.10.1 Rexahn Pharmaceuticals Corporation Information
11.10.2 Rexahn Pharmaceuticals Description and Business Overview
11.10.3 Rexahn Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Products Offered
11.10.5 Rexahn Pharmaceuticals Related Developments
11.1 Merck & Co., Inc.
11.1.1 Merck & Co., Inc. Corporation Information
11.1.2 Merck & Co., Inc. Description and Business Overview
11.1.3 Merck & Co., Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Merck & Co., Inc. Renal Cell Cacinoma Drugs Products Offered
11.1.5 Merck & Co., Inc. Related Developments
11.12 Cerulean Pharma Inc
11.12.1 Cerulean Pharma Inc Corporation Information
11.12.2 Cerulean Pharma Inc Description and Business Overview
11.12.3 Cerulean Pharma Inc Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Cerulean Pharma Inc Products Offered
11.12.5 Cerulean Pharma Inc Related Developments
11.13 Celldex Therapeutics
11.13.1 Celldex Therapeutics Corporation Information
11.13.2 Celldex Therapeutics Description and Business Overview
11.13.3 Celldex Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Celldex Therapeutics Products Offered
11.13.5 Celldex Therapeutics Related Developments
11.14 TVAX Biomedical
11.14.1 TVAX Biomedical Corporation Information
11.14.2 TVAX Biomedical Description and Business Overview
11.14.3 TVAX Biomedical Sales, Revenue and Gross Margin (2015-2020)
11.14.4 TVAX Biomedical Products Offered
11.14.5 TVAX Biomedical Related Developments
11.15 TRACON Pharmaceuticals
11.15.1 TRACON Pharmaceuticals Corporation Information
11.15.2 TRACON Pharmaceuticals Description and Business Overview
11.15.3 TRACON Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.15.4 TRACON Pharmaceuticals Products Offered
11.15.5 TRACON Pharmaceuticals Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Renal Cell Cacinoma Drugs Market Estimates and Projections by Region
12.1.1 Global Renal Cell Cacinoma Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Renal Cell Cacinoma Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Renal Cell Cacinoma Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Renal Cell Cacinoma Drugs Sales Forecast (2021-2026)
12.2.2 North America: Renal Cell Cacinoma Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Renal Cell Cacinoma Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Renal Cell Cacinoma Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Renal Cell Cacinoma Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Renal Cell Cacinoma Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Renal Cell Cacinoma Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Renal Cell Cacinoma Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Renal Cell Cacinoma Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Renal Cell Cacinoma Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Renal Cell Cacinoma Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Renal Cell Cacinoma Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Renal Cell Cacinoma Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Renal Cell Cacinoma Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Renal Cell Cacinoma Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Renal Cell Cacinoma Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Renal Cell Cacinoma Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Renal Cell Cacinoma Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Renal Cell Cacinoma Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Renal Cell Cacinoma Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Renal Cell Cacinoma Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Renal Cell Cacinoma Drugs Market Segments
Table 2. Ranking of Global Top Renal Cell Cacinoma Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Renal Cell Cacinoma Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Sutent(Sunitinib)
Table 5. Major Manufacturers of Nexavar(Sorafenib)
Table 6. Major Manufacturers of Votrient(Pazopanib)
Table 7. Major Manufacturers of Avastin(Bevacizumab)
Table 8. Major Manufacturers of Afinitor(Everolimus)
Table 9. Major Manufacturers of Inlyta(Axitinib)
Table 10. Major Manufacturers of Torisel(Temsirolimus)
Table 11. Major Manufacturers of Proleukin(Aldesleukin)
Table 12. Global Renal Cell Cacinoma Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 13. Global Renal Cell Cacinoma Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 14. Global Renal Cell Cacinoma Drugs Sales by Regions 2015-2020 (K Pcs)
Table 15. Global Renal Cell Cacinoma Drugs Sales Market Share by Regions (2015-2020)
Table 16. Global Renal Cell Cacinoma Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 17. Global Renal Cell Cacinoma Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 18. Global Renal Cell Cacinoma Drugs Sales Share by Manufacturers (2015-2020)
Table 19. Global Renal Cell Cacinoma Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Renal Cell Cacinoma Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Renal Cell Cacinoma Drugs as of 2019)
Table 21. Renal Cell Cacinoma Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Renal Cell Cacinoma Drugs Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Renal Cell Cacinoma Drugs Price (2015-2020) (USD/Pcs)
Table 24. Renal Cell Cacinoma Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Renal Cell Cacinoma Drugs Product Type
Table 26. Date of International Manufacturers Enter into Renal Cell Cacinoma Drugs Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Renal Cell Cacinoma Drugs Sales by Type (2015-2020) (K Pcs)
Table 29. Global Renal Cell Cacinoma Drugs Sales Share by Type (2015-2020)
Table 30. Global Renal Cell Cacinoma Drugs Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Renal Cell Cacinoma Drugs Revenue Share by Type (2015-2020)
Table 32. Renal Cell Cacinoma Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 33. Global Renal Cell Cacinoma Drugs Sales by Application (2015-2020) (K Pcs)
Table 34. Global Renal Cell Cacinoma Drugs Sales Share by Application (2015-2020)
Table 35. North America Renal Cell Cacinoma Drugs Sales by Country (2015-2020) (K Pcs)
Table 36. North America Renal Cell Cacinoma Drugs Sales Market Share by Country (2015-2020)
Table 37. North America Renal Cell Cacinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 38. North America Renal Cell Cacinoma Drugs Revenue Market Share by Country (2015-2020)
Table 39. North America Renal Cell Cacinoma Drugs Sales by Type (2015-2020) (K Pcs)
Table 40. North America Renal Cell Cacinoma Drugs Sales Market Share by Type (2015-2020)
Table 41. North America Renal Cell Cacinoma Drugs Sales by Application (2015-2020) (K Pcs)
Table 42. North America Renal Cell Cacinoma Drugs Sales Market Share by Application (2015-2020)
Table 43. Europe Renal Cell Cacinoma Drugs Sales by Country (2015-2020) (K Pcs)
Table 44. Europe Renal Cell Cacinoma Drugs Sales Market Share by Country (2015-2020)
Table 45. Europe Renal Cell Cacinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 46. Europe Renal Cell Cacinoma Drugs Revenue Market Share by Country (2015-2020)
Table 47. Europe Renal Cell Cacinoma Drugs Sales by Type (2015-2020) (K Pcs)
Table 48. Europe Renal Cell Cacinoma Drugs Sales Market Share by Type (2015-2020)
Table 49. Europe Renal Cell Cacinoma Drugs Sales by Application (2015-2020) (K Pcs)
Table 50. Europe Renal Cell Cacinoma Drugs Sales Market Share by Application (2015-2020)
Table 51. Asia Pacific Renal Cell Cacinoma Drugs Sales by Region (2015-2020) (K Pcs)
Table 52. Asia Pacific Renal Cell Cacinoma Drugs Sales Market Share by Region (2015-2020)
Table 53. Asia Pacific Renal Cell Cacinoma Drugs Revenue by Region (2015-2020) (US$ Million)
Table 54. Asia Pacific Renal Cell Cacinoma Drugs Revenue Market Share by Region (2015-2020)
Table 55. Asia Pacific Renal Cell Cacinoma Drugs Sales by Type (2015-2020) (K Pcs)
Table 56. Asia Pacific Renal Cell Cacinoma Drugs Sales Market Share by Type (2015-2020)
Table 57. Asia Pacific Renal Cell Cacinoma Drugs Sales by Application (2015-2020) (K Pcs)
Table 58. Asia Pacific Renal Cell Cacinoma Drugs Sales Market Share by Application (2015-2020)
Table 59. Latin America Renal Cell Cacinoma Drugs Sales by Country (2015-2020) (K Pcs)
Table 60. Latin America Renal Cell Cacinoma Drugs Sales Market Share by Country (2015-2020)
Table 61. Latin Americaa Renal Cell Cacinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 62. Latin America Renal Cell Cacinoma Drugs Revenue Market Share by Country (2015-2020)
Table 63. Latin America Renal Cell Cacinoma Drugs Sales by Type (2015-2020) (K Pcs)
Table 64. Latin America Renal Cell Cacinoma Drugs Sales Market Share by Type (2015-2020)
Table 65. Latin America Renal Cell Cacinoma Drugs Sales by Application (2015-2020) (K Pcs)
Table 66. Latin America Renal Cell Cacinoma Drugs Sales Market Share by Application (2015-2020)
Table 67. Middle East and Africa Renal Cell Cacinoma Drugs Sales by Country (2015-2020) (K Pcs)
Table 68. Middle East and Africa Renal Cell Cacinoma Drugs Sales Market Share by Country (2015-2020)
Table 69. Middle East and Africa Renal Cell Cacinoma Drugs Revenue by Country (2015-2020) (US$ Million)
Table 70. Middle East and Africa Renal Cell Cacinoma Drugs Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Renal Cell Cacinoma Drugs Sales by Type (2015-2020) (K Pcs)
Table 72. Middle East and Africa Renal Cell Cacinoma Drugs Sales Market Share by Type (2015-2020)
Table 73. Middle East and Africa Renal Cell Cacinoma Drugs Sales by Application (2015-2020) (K Pcs)
Table 74. Middle East and Africa Renal Cell Cacinoma Drugs Sales Market Share by Application (2015-2020)
Table 75. Merck & Co., Inc. Corporation Information
Table 76. Merck & Co., Inc. Description and Major Businesses
Table 77. Merck & Co., Inc. Renal Cell Cacinoma Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Merck & Co., Inc. Product
Table 79. Merck & Co., Inc. Recent Development
Table 80. Exelixis Inc Corporation Information
Table 81. Exelixis Inc Description and Major Businesses
Table 82. Exelixis Inc Renal Cell Cacinoma Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Exelixis Inc Product
Table 84. Exelixis Inc Recent Development
Table 85. Argus Therapeutics, Inc. Corporation Information
Table 86. Argus Therapeutics, Inc. Description and Major Businesses
Table 87. Argus Therapeutics, Inc. Renal Cell Cacinoma Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Argus Therapeutics, Inc. Product
Table 89. Argus Therapeutics, Inc. Recent Development
Table 90. Bristol-Myers Squibb Corporation Information
Table 91. Bristol-Myers Squibb Description and Major Businesses
Table 92. Bristol-Myers Squibb Renal Cell Cacinoma Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Bristol-Myers Squibb Product
Table 94. Bristol-Myers Squibb Recent Development
Table 95. Genentech Corporation Information
Table 96. Genentech Description and Major Businesses
Table 97. Genentech Renal Cell Cacinoma Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Genentech Product
Table 99. Genentech Recent Development
Table 100. Immatics Biotechnologies Corporation Information
Table 101. Immatics Biotechnologies Description and Major Businesses
Table 102. Immatics Biotechnologies Renal Cell Cacinoma Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Immatics Biotechnologies Product
Table 104. Immatics Biotechnologies Recent Development
Table 105. AVEO Oncology Corporation Information
Table 106. AVEO Oncology Description and Major Businesses
Table 107. AVEO Oncology Renal Cell Cacinoma Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. AVEO Oncology Product
Table 109. AVEO Oncology Recent Development
Table 110. Eisai Corporation Information
Table 111. Eisai Description and Major Businesses
Table 112. Eisai Renal Cell Cacinoma Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 113. Eisai Product
Table 114. Eisai Recent Development
Table 115. Acceleron Corporation Information
Table 116. Acceleron Description and Major Businesses
Table 117. Acceleron Renal Cell Cacinoma Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 118. Acceleron Product
Table 119. Acceleron Recent Development
Table 120. Rexahn Pharmaceuticals Corporation Information
Table 121. Rexahn Pharmaceuticals Description and Major Businesses
Table 122. Rexahn Pharmaceuticals Renal Cell Cacinoma Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Rexahn Pharmaceuticals Product
Table 124. Rexahn Pharmaceuticals Recent Development
Table 125. Bionomics Corporation Information
Table 126. Bionomics Description and Major Businesses
Table 127. Bionomics Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Bionomics Product
Table 129. Bionomics Recent Development
Table 130. Cerulean Pharma Inc Corporation Information
Table 131. Cerulean Pharma Inc Description and Major Businesses
Table 132. Cerulean Pharma Inc Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Cerulean Pharma Inc Product
Table 134. Cerulean Pharma Inc Recent Development
Table 135. Celldex Therapeutics Corporation Information
Table 136. Celldex Therapeutics Description and Major Businesses
Table 137. Celldex Therapeutics Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. Celldex Therapeutics Product
Table 139. Celldex Therapeutics Recent Development
Table 140. TVAX Biomedical Corporation Information
Table 141. TVAX Biomedical Description and Major Businesses
Table 142. TVAX Biomedical Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. TVAX Biomedical Product
Table 144. TVAX Biomedical Recent Development
Table 145. TRACON Pharmaceuticals Corporation Information
Table 146. TRACON Pharmaceuticals Description and Major Businesses
Table 147. TRACON Pharmaceuticals Renal Cell Cacinoma Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 148. TRACON Pharmaceuticals Product
Table 149. TRACON Pharmaceuticals Recent Development
Table 150. Global Renal Cell Cacinoma Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 151. Global Renal Cell Cacinoma Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 152. Global Renal Cell Cacinoma Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 153. Global Renal Cell Cacinoma Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 154. North America: Renal Cell Cacinoma Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 155. North America: Renal Cell Cacinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 156. Europe: Renal Cell Cacinoma Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 157. Europe: Renal Cell Cacinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 158. Asia Pacific: Renal Cell Cacinoma Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 159. Asia Pacific: Renal Cell Cacinoma Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 160. Latin America: Renal Cell Cacinoma Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 161. Latin America: Renal Cell Cacinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 162. Middle East and Africa: Renal Cell Cacinoma Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 163. Middle East and Africa: Renal Cell Cacinoma Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 164. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 165. Key Challenges
Table 166. Market Risks
Table 167. Main Points Interviewed from Key Renal Cell Cacinoma Drugs Players
Table 168. Renal Cell Cacinoma Drugs Customers List
Table 169. Renal Cell Cacinoma Drugs Distributors List
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. Renal Cell Cacinoma Drugs Product Picture
Figure 2. Global Renal Cell Cacinoma Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Sutent(Sunitinib) Product Picture
Figure 4. Nexavar(Sorafenib) Product Picture
Figure 5. Votrient(Pazopanib) Product Picture
Figure 6. Avastin(Bevacizumab) Product Picture
Figure 7. Afinitor(Everolimus) Product Picture
Figure 8. Inlyta(Axitinib) Product Picture
Figure 9. Torisel(Temsirolimus) Product Picture
Figure 10. Proleukin(Aldesleukin) Product Picture
Figure 11. Global Renal Cell Cacinoma Drugs Sales Market Share by Application in 2020 & 2026
Figure 12. Mucinous Tubular and Spindle Cell Carcinoma (MTSCC)
Figure 13. Multilocular Cystic Clear Cell Renal Cell Carcinoma
Figure 14. Tubulocystic Renal Cell Carcinoma
Figure 15. Thyroid-Like Follicular Renal Cell Carcinoma
Figure 16. Others
Figure 17. Renal Cell Cacinoma Drugs Report Years Considered
Figure 18. Global Renal Cell Cacinoma Drugs Market Size 2015-2026 (US$ Million)
Figure 19. Global Renal Cell Cacinoma Drugs Sales 2015-2026 (K Pcs)
Figure 20. Global Renal Cell Cacinoma Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 21. Global Renal Cell Cacinoma Drugs Sales Market Share by Region (2015-2020)
Figure 22. Global Renal Cell Cacinoma Drugs Sales Market Share by Region in 2019
Figure 23. Global Renal Cell Cacinoma Drugs Revenue Market Share by Region (2015-2020)
Figure 24. Global Renal Cell Cacinoma Drugs Revenue Market Share by Region in 2019
Figure 25. Global Renal Cell Cacinoma Drugs Sales Share by Manufacturer in 2019
Figure 26. The Top 10 and 5 Players Market Share by Renal Cell Cacinoma Drugs Revenue in 2019
Figure 27. Renal Cell Cacinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Renal Cell Cacinoma Drugs Sales Market Share by Type (2015-2020)
Figure 29. Global Renal Cell Cacinoma Drugs Sales Market Share by Type in 2019
Figure 30. Global Renal Cell Cacinoma Drugs Revenue Market Share by Type (2015-2020)
Figure 31. Global Renal Cell Cacinoma Drugs Revenue Market Share by Type in 2019
Figure 32. Global Renal Cell Cacinoma Drugs Market Share by Price Range (2015-2020)
Figure 33. Global Renal Cell Cacinoma Drugs Sales Market Share by Application (2015-2020)
Figure 34. Global Renal Cell Cacinoma Drugs Sales Market Share by Application in 2019
Figure 35. Global Renal Cell Cacinoma Drugs Revenue Market Share by Application (2015-2020)
Figure 36. Global Renal Cell Cacinoma Drugs Revenue Market Share by Application in 2019
Figure 37. North America Renal Cell Cacinoma Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 38. North America Renal Cell Cacinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 39. North America Renal Cell Cacinoma Drugs Sales Market Share by Country in 2019
Figure 40. North America Renal Cell Cacinoma Drugs Revenue Market Share by Country in 2019
Figure 41. U.S. Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 42. U.S. Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. Canada Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 44. Canada Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. North America Renal Cell Cacinoma Drugs Market Share by Type in 2019
Figure 46. North America Renal Cell Cacinoma Drugs Market Share by Application in 2019
Figure 47. Europe Renal Cell Cacinoma Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 48. Europe Renal Cell Cacinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 49. Europe Renal Cell Cacinoma Drugs Sales Market Share by Country in 2019
Figure 50. Europe Renal Cell Cacinoma Drugs Revenue Market Share by Country in 2019
Figure 51. Germany Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Germany Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. France Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. France Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. U.K. Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. U.K. Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Italy Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 58. Italy Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Russia Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 60. Russia Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Europe Renal Cell Cacinoma Drugs Market Share by Type in 2019
Figure 62. Europe Renal Cell Cacinoma Drugs Market Share by Application in 2019
Figure 63. Asia Pacific Renal Cell Cacinoma Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 64. Asia Pacific Renal Cell Cacinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 65. Asia Pacific Renal Cell Cacinoma Drugs Sales Market Share by Region in 2019
Figure 66. Asia Pacific Renal Cell Cacinoma Drugs Revenue Market Share by Region in 2019
Figure 67. China Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. China Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Japan Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Japan Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. South Korea Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. South Korea Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. India Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. India Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Australia Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Australia Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Taiwan Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Taiwan Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Indonesia Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Indonesia Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Thailand Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Thailand Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Malaysia Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Malaysia Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Philippines Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 86. Philippines Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Vietnam Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 88. Vietnam Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Asia Pacific Renal Cell Cacinoma Drugs Market Share by Type in 2019
Figure 90. Asia Pacific Renal Cell Cacinoma Drugs Market Share by Application in 2019
Figure 91. Latin America Renal Cell Cacinoma Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 92. Latin America Renal Cell Cacinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 93. Latin America Renal Cell Cacinoma Drugs Sales Market Share by Country in 2019
Figure 94. Latin America Renal Cell Cacinoma Drugs Revenue Market Share by Country in 2019
Figure 95. Mexico Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Mexico Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Brazil Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 98. Brazil Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 99. Argentina Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 100. Argentina Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Latin America Renal Cell Cacinoma Drugs Market Share by Type in 2019
Figure 102. Latin America Renal Cell Cacinoma Drugs Market Share by Application in 2019
Figure 103. Middle East and Africa Renal Cell Cacinoma Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 104. Middle East and Africa Renal Cell Cacinoma Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 105. Middle East and Africa Renal Cell Cacinoma Drugs Sales Market Share by Country in 2019
Figure 106. Middle East and Africa Renal Cell Cacinoma Drugs Revenue Market Share by Country in 2019
Figure 107. Turkey Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. Turkey Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Saudi Arabia Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 110. Saudi Arabia Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 111. U.A.E Renal Cell Cacinoma Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 112. U.A.E Renal Cell Cacinoma Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 113. Middle East and Africa Renal Cell Cacinoma Drugs Market Share by Type in 2019
Figure 114. Middle East and Africa Renal Cell Cacinoma Drugs Market Share by Application in 2019
Figure 115. North America Renal Cell Cacinoma Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. North America Renal Cell Cacinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Europe Renal Cell Cacinoma Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Europe Renal Cell Cacinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Asia Pacific Renal Cell Cacinoma Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Asia Pacific Renal Cell Cacinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Latin America Renal Cell Cacinoma Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 122. Latin America Renal Cell Cacinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Middle East and Africa Renal Cell Cacinoma Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 124. Middle East and Africa Renal Cell Cacinoma Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Porter's Five Forces Analysis
Figure 126. Channels of Distribution
Figure 127. Distributors Profiles
Figure 128. Bottom-up and Top-down Approaches for This Report
Figure 129. Data Triangulation
Figure 130. Key Executives Interviewed
腎細胞がん治療薬の世界市場（～2026年） Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases.The drug is …- 高度腎細胞癌治療薬の世界市場（～2026年） Advanced renal cell carcinoma is associated with a type of kidney cancer that appears in the covering of the proximal complex tubule. The convoluted tubule is a very small part of tubes in the kidney that helps in transportation of unwanted particles from the blood to the urine. Advanced renal cell …
- 腎臓/腎がん治療薬の世界市場（～2026年） Kidney/Renal Cancer Drugs are used to cure kidney cancers. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors bo…
- 末期腎疾患（ESRD）治療薬の世界市場（～2026年） Market Analysis and Insights: Global End-Stage Renal Disease (ESRD) Drugs Market The global End-Stage Renal Disease (ESRD) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global End-Stage Renal Disease (ESRD) Drugs Scop…
- 急性腎不全治療薬の世界市場（～2026年） Acute renal failure is a sudden loss of kidney’s ability to eliminate excess fluids, salts and metabolic waste from the body. It leads to accumulation of metabolic waste and electrolytes in the body which can be life-threatening. Kidney eliminates creatinine (Metabolic waste) from the body. Acute re…